Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers

Alan L. Williams; Raquelle S. Newman

doi:10.1370/afm.240184

Article Figures & Data

Figures

Tables
Additional Files

Download figure
Open in new tab
Download powerpoint
Figure 1.
Data Flowchart for Inclusion Based on Hepatitis B Titer and Vaccine History

Tables

Figures
Additional Files

View popup

Table 1.

Response to Single Booster Dose of Hepatitis B Vaccine in Previously Vaccinated Military Medical Students^{^a}

	Standard vaccine booster	Heplisav-B booster
Sample size	n = 82	n = 160
Years between first series and first anti-HBs titer, mean (SD)	21.5 (4.7)	21.1 (4.2)
anti-HBs <10 mIU/mL^{^b}	6	1
anti-HBs ≥10 mIU/mL^{^b}	76 (92.7%)	159 (99.4%)
Percent difference	6.7%
X² comparison of proportions	(95% CI, 1.9%-14.5%); P = .003

anti-HBs = hepatitis B surface antigen antibody.
↵a All participants received 3 or 4 doses of standard hepatitis B vaccine before their initial titer.
↵b Follow-up titers drawn ≥30 days after booster vaccine.

SUPPLEMENTAL DATA IN PDF FILE BELOW

Williams_Supp_Figs_1-2.pdf -
Supplemental Figures 1-2. Post-booster titer distribution
VISUAL ABSTRACT IN PDF FILE BELOW

Williams_VA_Final.pdf -
PDF file
PLAIN-LANGUAGE SUMMARY

Research Brief

Newer Hepatitis B Vaccine Shows Promise as Booster for Health Care Workers

Background and Goal: Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body fluids. They are considered protected if they have a hepatitis B surface antigen antibody (anti-HBs) titer of ≥10 mIU/mL after completing a full vaccination series.This study compared the effectiveness of Heplisav-B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals.

Study Approach: Researchers conducted a retrospective cohort study at the Uniformed Services University of the Health Sciences, analyzing medical records from 2019 to 2022. The study included medical students who had completed a full hepatitis B vaccine series but had low antibody levels. Participants received either a standard hepatitis B booster or a Heplisav-B booster. Their antibody levels were measured at least 30 days later to determine if they had achieved protective immunity.

Main Results:

99.4% of individuals receiving Heplisav-B reached protective antibody levels.

92.7% of individuals receiving a standard booster reached protective levels.

The 6.7% higher response rate with Heplisav-B was statistically significant (95% CI, 1.9%-14.5%; P = .003).

All seven individuals who remained below protective levels after one booster reached immunity after receiving additional vaccinations.

Why It Matters:The study findings suggest that a single booster dose is sufficient to confirm hepatitis B immunity in most young, healthy health care workers who previously completed a full vaccination series. Heplisav-B was more effective than standard hepatitis B vaccines.

Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers

Alan L. Williams, MD, MPH

Department of Family Medicine, Uniformed Services University, Bethesda, Maryland

Raquelle S. Newman, MD

Spangdahlem Air Base, 54529 Spangdahlem, AE, Germany

Visual Abstract: